127 related articles for article (PubMed ID: 32929128)
1. Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.
Kuroda Y; Yashima-Abo A; Koyama D; Kikuchi J; Mori S; Ito S; Furukawa Y
Leukemia; 2021 May; 35(5):1506-1510. PubMed ID: 32929128
[No Abstract] [Full Text] [Related]
2. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.
Huang S; Jiang C; Zhang H; Bell T; Guo H; Liu Y; Yao Y; Zeng D; Ahmed M; Nomie K; Zhang L; Wang M
Blood Cancer J; 2018 Mar; 8(3):33. PubMed ID: 29559616
[No Abstract] [Full Text] [Related]
3. Orbital mantle cell lymphoma presenting as myasthenia gravis.
Karlin J; Peck T; Prenshaw K; Portell CA; Kirzhner M
Orbit; 2017 Dec; 36(6):365-369. PubMed ID: 28820310
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.
Medina DJ; Goodell L; Glod J; Gélinas C; Rabson AB; Strair RK
Haematologica; 2012 Aug; 97(8):1255-63. PubMed ID: 22371181
[TBL] [Abstract][Full Text] [Related]
5. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
7. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.
Peitsch WK
J Dtsch Dermatol Ges; 2019 Mar; 17(3):330-332. PubMed ID: 30775841
[No Abstract] [Full Text] [Related]
8. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
[TBL] [Abstract][Full Text] [Related]
9. Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.
Mori S; Patel RD; Ahmad S; Varela J; Smith T; Altoos R; Shen Q; Goldstein SC; Persky DO
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):e93-e97. PubMed ID: 30559058
[No Abstract] [Full Text] [Related]
10. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
12. Maintenance rituximab in mantle-cell lymphoma.
Burki TK
Lancet Oncol; 2017 Nov; 18(11):e647. PubMed ID: 28988912
[No Abstract] [Full Text] [Related]
13. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
14. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
15. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
16. Viral encephalitis associated with rituximab maintenance therapy: two cases and a review of literature.
Noij DP; den Heijer T; van Zaanen HCT
Neth J Med; 2020 Feb; 78(1):37-40. PubMed ID: 32043478
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-associated colitis.
Barreiro Alonso E; Álvarez Álvarez A; Tojo González R; de la Coba Ortiz C
Gastroenterol Hepatol; 2019 Apr; 42(4):251-252. PubMed ID: 29884483
[No Abstract] [Full Text] [Related]
18. Recurrent monomorphic epitheliotropic intestinal T-cell lymphoma with aberrant CD20 expression: An implication for anti-CD20 (rituximab) antibody therapy?
Liao PH; Chou SC; Huang WT; Su YZ; Wang MC; Chuang SS
Pathol Int; 2018 Dec; 68(12):712-714. PubMed ID: 30402988
[No Abstract] [Full Text] [Related]
19. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
Seggewiss R; Ho AD; Kraemer A
Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
[TBL] [Abstract][Full Text] [Related]
20. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
